RegMed Investors’ (RMi) pre-open: get it up

June 24, 2025 7:44am

The cell and gene therapy sector that is …

I am hoping to de-escalate “uncle algo and his electronic trading dwarfs” from selling

Pre-open Indications: 5 Positive and 1 Negative

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

Monday’s night’s … RegMed Investors (RMi) Closing Bell: RegMed Investors (RMi) Closing Bell: Sector has minor collateral damage … https://www.regmedinvestors.com/articles/13970

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

Tuesday: The pre-open Dow futures are UP +0.63% or (+269 points), the S&P futures are UP +0.75% or (+45 points) and the Nasdaq futures are UP +1% or (+220 points)

• Stock futures rose Tuesday, 6/24,
• European stocks opened +1% higher,
• Asia-Pacific markets rose.

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

• Monday: The Dow closed UP +374.96 points or +0.89%, the S&P closed UP +57.35 points or +0.96% while the Nasdaq closed UP +183.57 points or +0.94%
• Friday: The Dow closed UP +35.18 points or +0.08%, the S&P closed DOWN -13.03 points or -0.22% while the Nasdaq closed DOWN -98.86 points or -0.51%
• Last week: The S&P 500 lost -0.2%, Dow had a 0.2% gain and the Nasdaq advanced +0.2%
• The previous week: The S&P 500 lost -0.4%, the Dow fell 1.3% while the Nasdaq slid -0.6%

Economic Data Docket: S&P Flash U.S. manufacturing and services PMI plus Existing home sales

Q2 – June – 1 market holiday, 6 negative, 1 neutral and 9 positive closes

• May – 1 market holiday, 10 negative and 11 positive closes
• Q2 - April – 10 negative and 11 positive closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• It is still a mix of ups, downs and just uncertainty

Pre-open Indications:

Vericel (VCEL) closed down -$0.22 with a positive +$1.22 or +4.07% aftermarket

Regenxbio (RGNX) closed down -$0.57 with a positive +$0.20 or +2.54% pre-open

Solid Biosciences (SLDB) closed down -$0.28 after Friday’s +$0.14 with a negative -$0.06 or -1.33% aftermarket

uniQure NV (QURE) closed down -$0.26 after Friday’s -$0.89 with a positive +$0.15 or +1.08% pre-open 

Editas Medicine (EDIT) closed down -$0.12 after Friday’s -$0.13 with a positive +$0.01 or +0.45% aftermarket

Moderna (MRNA) closed down -$0.23 with a positive +$0.25 or +0.97% pre-open

The BOTTOM LINE: New week <6/23 to 6/27> 1^st session, Monday closed negative while slowing coming to a month’s end <Monday, 6/30>.

New of what’s in the wind:

Leap Therapeutics (Nasdaq: LPTX) has run out of runway. As its stock is down -$0.0680 to $0.30. Its share price is down almost 90% so far this year, but rose slightly following its Monday announcement, giving it a market cap of $16 million, which is less than the $33 million in cash it last reported as of March 31.

• The Cambridge biotech is reducing internal spending — including laying off workers and winding down its clinical trial — as it opens up the search for strategic alternatives. In a securities filing on Monday, Leap cited “current market conditions and the financial position” of the company for its decision.
• This is the 2^nd time this year LPTX has reduced its workforce. Leap came into 2025 with 52 full-time employees.
• In May, the biotech let go of 50% of its staff, leaving it with around 26 workers. Its latest round of cuts will impact 75% of its remaining employees, eventually leaving Leap with around 6 people.
• Following its May layoffs, Leao said it would funnel resources into the clinical development of sirexatamab in second-line colorectal cancer patients and another drug, FL-501, in preclinical development.
• Now, LPTX is looking for potential sale or partnership opportunities for sirexatamab and FL-501.
• Leap has said that the data supports taking sirexatamab into a P3 clinical trial. On Monday, CEO Douglas Onsi added that updated data from part of a P2 study of sirexatamab “demonstrated a statistically significant benefit in patients” they were targeting.  <Boston business Journal>
• LPTX does not have the resources to bring sirexatamab further along by itself.
• LPTX’s board has brought on Raymond James & Associates Inc. as its financial advisor in this process.

Interesting Info this month of June: The M&A list evolves: Blueprint Medicine (BPMC) by Bristol Meyers (BMY), Sage Therapeutics by Supernus Pharmaceuticals (SUPN), CureVac (CVAC) by BioNTech (BNTX) and now Verve Therapeutics (VERV) by Eli Lilly (LLY)

June ’25: understand the “flow” of markets, the cell and gene therapy sector and economic karma…

• 6/23 - Monday closed negative with 15 positive, 16 negative and 4 flats

• 6/20 - Friday closed negative with 14 positive, 18 negative and 3 flats
• 5/19 – Thursday was a market holiday
• 6/18 – Wednesday closed positive with 21 positive, 11 negative and 3 flats
• 6/17 - Tuesday closed negative with 10 positive, 23 negative and 2 flats
• 6/16 - Monday closed positive with 20 positive, 11 negative and 4 flats

• 6/13 - Friday closed negative with 5 positive, 25 negative and 5 flats
• 6/12 – Thursday closed negative with 7 positive, 23 negative and 5 flats
• 6/11 – Wednesday closed negative with 6 positive, 25 negative and 4 flats
• 6/10 - Tuesday closed positive with 17 positive, 15 negative and 3 flats
• 6/9 - Monday closed neutral with 16 positive, 16 negative and 3 flats

• 6/6 – Friday negative with 4 positive, 28 negative and 3 flats
• 6/5 - Thursday closed positive with 16 positive, 15 negative and 4 flats
• 6/4 – Wednesday closed positive with 18 positive, 13 negative and 4 flats
• 6/3 - Tuesday closed positive with 24 positive, 8 negative and 3 flats
• 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

• Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, brace ourself for more volatility re Middle East "tensions", economics and their trending effects!

Welcome to my world of defining the “grey’ in our universe!

• The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.